Evidence map›Paper›PMID 26210683›Full record

ArticleUrologic oncology2015

Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States.

Christopher B Allard, Francisco Gelpi-Hammerschmidt, Lauren C Harshman, Toni K Choueiri, Izak Faiena, Parth Modi, Benjamin I Chung, Ilker Tinay, Eric A Singer, Steven L Chang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Urologic oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Trends in comorbidity, acuity, and maternal risk associated with preeclampsia across obstetric volume settings.The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 2019
    Article
  14. Article
  15. Review
  16. Observational
  17. Article
  18. Review
  19. Article
  20. [Genitourinary malignancies and rheumatoid arthritis].Zeitschrift fur Rheumatologie · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Christopher B AllardDivision of Urology, Brigham and Women׳s Hospital, Harvard Medical School, Boston, MA; Department of Urology, Massachusetts General Hospital, Boston, MA. Electronic address: Callard@mgh.harvard.edu.
Francisco Gelpi-HammerschmidtDivision of Urology, Brigham and Women׳s Hospital, Harvard Medical School, Boston, MA; Department of Urology, Massachusetts General Hospital, Boston, MA.
Lauren C HarshmanKidney Cancer Center, Dana-Farber Cancer Institute, Brigham and Women׳s Hospital, Harvard Medical School, Boston, MA.
Toni K ChoueiriKidney Cancer Center, Dana-Farber Cancer Institute, Brigham and Women׳s Hospital, Harvard Medical School, Boston, MA.
Izak FaienaSection of Urologic Oncology, Rutgers Institute of New Jersey and Robert Wood Johnson Medical School, New Brunswick, NJ.
Parth ModiSection of Urologic Oncology, Rutgers Institute of New Jersey and Robert Wood Johnson Medical School, New Brunswick, NJ.
Benjamin I ChungDepartment of Urology, Stanford School of Medicine, Palo Alto, CA.
Ilker TinayDivision of Urology, Brigham and Women׳s Hospital, Harvard Medical School, Boston, MA; Department of Urology, Marmara University School of Medicine, Istanbul, Turkey.
Eric A SingerSection of Urologic Oncology, Rutgers Institute of New Jersey and Robert Wood Johnson Medical School, New Brunswick, NJ.
Steven L ChangDivision of Urology, Brigham and Women׳s Hospital, Harvard Medical School, Boston, MA.
Rutgers, The State University of New Jersey · USDana-Farber Cancer Institute · USMassachusetts General Hospital · USBrigham and Women's Hospital · USHarvard University · USStanford Medicine · US

Funding

TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Chang S Chan · 1997 to 2026
$94.5M
Treating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Wanling Xie · 2003 to 2026
$53.4M
NCI NIH HHS 5P50CA101942-09NCI NIH HHS P30 CA072720NCI NIH HHS P30CA072720NCI NIH HHS P50 CA101942
6 · The paper itself

Abstract

backgroundTargeted therapies (TTs) have revolutionized metastatic renal cell carcinoma (mRCC) treatment in the past decade, largely replacing immunotherapy including high-dose interleukin-2 (HD IL-2) therapy. We evaluated trends in HD IL-2 use for mRCC in the TT era.

methodsOur cohort comprised a weighted estimate of all patients undergoing HD IL-2 treatment for mRCC from 2004 to 2012 using the Premier Hospital Database. We assessed temporal trends in HD IL-2 use including patient, disease, and hospital characteristics stratified by era (pre-TT uptake: 2004-2006, uptake: 2007-2009, and post-TT uptake: 2010-2012) and fitted multivariable regression models to identify predictors of treatment toxicity and tolerability.

resultsAn estimated 2,351 patients received HD IL-2 therapy for mRCC in the United States from 2004 to 2012. The use decreased from 2004 to 2008. HD IL-2 therapy became increasingly centralized in teaching hospitals (24% of treatments in 2004 and 89.5% in 2012). Most patients who received HD IL-2 therapy were men, white, younger than 60 years, had lung metastases, and were otherwise healthy. Vasopressors, intensive care unit admission, and hemodialysis were necessary in 53.4%, 33.0%, and 7.1%, respectively. Factors associated with toxicities in multivariable analyses included being unmarried, male sex, and multiple metastatic sites. African Americans and patients with single-site metastases were less likely to receive multiple treatment cycles.

conclusionsHD IL-2 therapy is used infrequently for mRCC in the United States, and its application has diminished with the uptake of TT. Patients are being increasingly treated in teaching hospitals, suggesting a centralization of care and possible barriers to access. A recent slight increase in HD IL-2 therapy use likely reflects recognition of the inability of TT to effect a complete response.

Indexed as

AgedAntineoplastic AgentsCarcinoma, Renal CellCohort StudiesDose-Response Relationship, DrugFemaleFollow-Up StudiesHumansInterleukin-2Kidney NeoplasmsMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPrognosisUnited StatesAntineoplastic AgentsInterleukin-2High-dose interleukin-2ImmunotherapyKidney cancerRenal cell carcinomaTherapy trendsToxicity

Identifiers

PMID26210683
PMCPMC5178830
OpenAlexW946192996

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.